Skip to main content

Advertisement

Table 2 Summary: within patient change for CCP+ status to VERA (progression) in both phases and CCP+ status to non-progression within patient change and vs. progressors from the validation phase

From: Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis

  CCP+ to VERA CCP+ to no progression CCP+ non progressor CCP+ progressor Progressors vs. non progressors
Median FC (IQR 1st, 3rd) Median FC (IQR 1st, 3rd) B/L median dCt (IQR) B/L median dCt (IQR) FD between medians Area under ROC curve (90% CI) Sens Spec
Pilot phase        
miR-22 4.3 (2.8, 12.1) - - - - - -
miR-382 4.1 (1.7, 6.9) - - -    
miR-486-3p 4.1 (0.9, 8.6) - - - - - -
Validation Phase        
miR-22 2.5 (-2.2, 15.3) 3.4 (2.3, 12.6) 7.4 (4.1, 8.2) 3.1 (1.8, 7.3) 19.7 0.68 (0.48, 0.82) 63% 100%
miR-382 1.2 (-2.1, 2.7) 2.4 (1.0, 2.6) 1.1 (0.0, 1.8) -0.2 (-0.5, 1.9) 2.5 0.57 (0.40, 0.75) 75% 58%
miR-486-3p 2.2 (-2.5, 6.0) 1.0 (-1.4, 3.0) 3.4 (1.7, 3.9) 3.9 (2.6, 5.0) -1.4 0.55 (0.36, 0.72) 50% 75%
  1. CCP anti-cyclic citrullinated peptide, VERA very early rheumatoid arthritis, miRNA microRNA, FC fold change, FD fold difference, B/L baseline (sample), IQR interquartile range, ROC receiver operating characteristic, Sens sensitivity, Spec specificity